Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Oric Pharmaceuticals (NASDAQ:ORIC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025